Related Experiment Video
Updated: Aug 12, 2025

Author Spotlight: Enhancing Graft Viability Assessment Through Quantitative Metrics and Innovative Reservoir Systems
Published on: August 2, 2024
COVID-19 in heart transplant recipients
Sepideh Taghavi1, Hoda Raffiei Jelodar2, Ali Rafati1
1Heart Valve Disease Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran.
Abstract:
After solid organ transplantation, patients require lifelong immunosuppressive medication, increasing susceptibility to COVID-19. We evaluated the clinical outcomes of heart transplant recipients in patients with COVID-19. We enrolled twenty-two COVID-19 cases of adult heart transplantation from February 2020 to September 2021. The most common symptoms in patients were fever and myalgia. The death occurred in 3 (13.6 %). Although heart transplantation mortality may increase in the acute rejection phase concomitant with COVID-19, immunosuppressive dose reduction may not be necessary for all heart transplant patients with COVID-19.
Related Concept Videos
Kidney Transplant I: Introduction
Tissue Transplantation
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
Cardiomyopathy V: Interprofessional Care
Kidney Transplant III: Nursing Management
Kidney Transplant II: Surgical Procedure
Exercise and Cardiovascular Response
Light to moderate physical activity initiates a series of interconnected responses in the body. The heart rate modestly increases in anticipation of the workout, followed by widespread vasodilation as oxygen consumption by skeletal muscles increases. This results in decreased peripheral resistance, increased capillary blood flow, and accelerated...

